Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 8,311 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care therapies Clear all
Terminated Phase 2 Interventional Results available

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Poorly Differentiated Thyroid Gland Carcinoma
Interventions
Lenvatinib, Sorafenib, Cabozantinib, Vandetanib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 9, 2026, 5:40 AM EDT
Suspended Phase 2 Interventional

ARN-75039 Lassa Fever Treatment in West Africa

NCT07419373
View directory record Official record
Conditions
Lassa Fever
Interventions
ARN-75039 high, Intravenous ribavirin, ARN-75039 low
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy

NCT01915056
View directory record Official record
Conditions
Cancer
Interventions
GA-driven Intervention
Other
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

NCT03850782
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost (SR)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
38
States / cities
Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

NCT02343159
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, Medication Event Monitoring System (MEMS), Adherence counseling
Drug · Device · Behavioral
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Homewood, Alabama • Pheonix, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

A Research Study for Latina Women With Breast Cancer

NCT04861896
View directory record Official record
Conditions
Cancer, Breast, Cancer-related Problem/Condition, Quality of Life, Hormone Dependent Neoplasms, Adherence, Medication
Interventions
"My Guide" (psychoeducation & self-management program)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Nativis Voyager for Newly Diagnosed GBM

NCT03276286
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nativis Voyager
Device
Lead sponsor
Nativis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Results available

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

NCT02327169
View directory record Official record
Conditions
Advanced Nonhematologic Malignancies
Interventions
MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

NCT06639854
View directory record Official record
Conditions
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
Interventions
Hematopoietic Cell Transplant, Letermovir
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

NCT00494494
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Primary Care Prevention of Stimulant Diversion by High School Students With ADHD

NCT03080259
View directory record Official record
Conditions
ADHD
Interventions
Stimulant Diversion Prevention (SDP)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 3 Interventional Results available

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

NCT03558984
View directory record Official record
Conditions
Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions
D-PLEX, Standard of Care
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Huston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Not yet recruiting Not applicable Interventional

TeleABA for Hospitalized Adolescents and Young Adults With Autism Spectrum Disorder

NCT07701915
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Standard Hospital Care, Telehealth Applied Behavior Analysis (TeleABA)
Behavioral
Lead sponsor
Caring Technologies, Inc.
Industry
Eligibility
12 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Neptune City, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

NCT04093024
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

NCT03581123
View directory record Official record
Conditions
Acute Pain, Low Back Pain, Mechanical
Interventions
Supported-Self Management (SSM), Spinal Manipulation Therapy (SMT), SMT + SSM, Standard Medical Care (SMC)
Behavioral · Other · Combination Product + 1 more
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation

NCT04357288
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Aid, Encounter Decision Aid
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Post COVID Fatigue

NCT05445427
View directory record Official record
Conditions
Post COVID Syndrome, Fatigue, Headache
Interventions
vagal nerve stimulator
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers

NCT07335861
View directory record Official record
Conditions
Venous Leg Ulcer, Chronic Wounds
Interventions
Hyalomatrix, Standard of Care
Device · Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Alexandria, Louisiana • Pineville, Louisiana • Vidalia, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated No phase listed Observational

Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

NCT05083741
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Chitogel, Nexfoam
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Not yet recruiting Not applicable Interventional

Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)

NCT07736729
View directory record Official record
Conditions
Obesity
Interventions
Biometric-informed care, Control Arm: Standard Care
Behavioral
Lead sponsor
Jeff Reeves
Other
Eligibility
18 Years to 64 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

NCT04505553
View directory record Official record
Conditions
Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Rectal Carcinoma, Small Intestinal Carcinoma, Anal Carcinoma, Digestive System Carcinoma, Digestive System Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor
Interventions
Acupuncture Therapy, Acupressure Therapy, Oral Cryotherapy, Questionnaire Administration, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 9, 2026, 5:40 AM EDT